Lista de obras - Eric Angevin - Dominio Público Uruguay

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification

artículo científico publicado en 2017

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors

artículo científico publicado en 2014

Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients

artículo científico publicado en 2004

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy

artículo científico publicado en 2015

Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells

artículo científico publicado en 2010

Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials

artículo científico publicado en 2016

Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma

artículo científico publicado en 1993

Communication en oncologie dans le cadre d’essais thérapeutiques de phase I : mise en œuvre et évaluation d’un programme de formation

artículo científico publicado en 2015

Cost analysis of adverse events associated with non-small cell lung cancer management in France

artículo científico

Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production

artículo científico publicado en 2001

Dendritic cell-based immunotherapy of cancer

artículo científico publicado en 2000

Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk.

artículo científico publicado en 2002

Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients

artículo científico publicado en 2002

Exosome-based immunotherapy

artículo científico publicado en 2004

Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides

artículo científico publicado en 2003

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells

artículo científico publicado en 2004

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection

artículo científico

Exosomes for cancer immunotherapy

artículo científico publicado en 2004

Exosomes in cancer immunotherapy: preclinical data

artículo científico publicado en 2001

FGFR inhibitor induced peripheral neuropathy in patients with advanced RCC.

artículo científico publicado en 2010

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers

artículo científico publicado en 2017

Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).

artículo científico publicado en 2000

IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules

artículo científico publicado en 2004

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

artículo científico publicado en 2016

Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2.

artículo científico publicado en 1994

In Vivo-Targeted Gene Delivery Using Antibody-Based Nonviral Vector

artículo científico publicado en 2002

In vitro generation of cytotoxic effectors activated by interleukin 2 (IL-2): comparison of autologous peripheral blood stem cells (PBSC) from adults and children

artículo científico publicado en 2001

Isolation and characterization of renal cancer stem cells from patient-derived xenografts

artículo científico publicado en 2015

Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma

artículo científico publicado en 2007

Low-dose IL-2 treatment: Activation of discrete T- and NK-cell sub-populationsin vivo

artículo científico publicado en 1995

Malignant effusions and immunogenic tumour-derived exosomes

artículo científico publicado en 2002

Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon γ: Immunological monitoring

artículo científico publicado en 1994

No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia. Multivirc Group

artículo científico publicado en 1998

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

artículo científico publicado en 2004

Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience

artículo científico publicado en 2015

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

artículo científico publicado en 2013

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

artículo científico publicado en 2017

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.

artículo científico publicado en 2015

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

artículo científico publicado en 2007

Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer

artículo científico publicado en 2014

Phase II trial of thalidomide in renal-cell carcinoma

artículo científico publicado en 2002

Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib

artículo científico publicado en 2013

Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts.

artículo científico publicado en 2011

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

artículo científico publicado en 2017

Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients

artículo científico publicado en 2003

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

artículo científico publicado en 2015

Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma

artículo científico publicado en 2004

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety

artículo científico publicado en 2011

T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines

artículo científico publicado en 1997

The decreased expression of CD3 ζ chains in cancer patients is not reversed BY IL-2 Administration

artículo científico publicado en 1994

Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: a 2-year experience

artículo científico publicado en 1995

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

artículo científico publicado en 2005

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings

artículo científico publicado en 2014

Lista de obras de Eric Angevin

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors

Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy

Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells

Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials

Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma

Communication en oncologie dans le cadre d’essais thérapeutiques de phase I : mise en œuvre et évaluation d’un programme de formation

Cost analysis of adverse events associated with non-small cell lung cancer management in France

Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production

Dendritic cell-based immunotherapy of cancer

Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk.

Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients

Exosome-based immunotherapy

Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection

Exosomes for cancer immunotherapy

Exosomes in cancer immunotherapy: preclinical data

FGFR inhibitor induced peripheral neuropathy in patients with advanced RCC.

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers

Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).

IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2.

In Vivo-Targeted Gene Delivery Using Antibody-Based Nonviral Vector

In vitro generation of cytotoxic effectors activated by interleukin 2 (IL-2): comparison of autologous peripheral blood stem cells (PBSC) from adults and children

Isolation and characterization of renal cancer stem cells from patient-derived xenografts

Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma

Low-dose IL-2 treatment: Activation of discrete T- and NK-cell sub-populationsin vivo

Malignant effusions and immunogenic tumour-derived exosomes

Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon γ: Immunological monitoring

No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia. Multivirc Group

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer

Phase II trial of thalidomide in renal-cell carcinoma

Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib

Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts.

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety

T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines

The decreased expression of CD3 ζ chains in cancer patients is not reversed BY IL-2 Administration

Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: a 2-year experience

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings